1. Adamis Pharmaceuticals said it received FDA approval for emergency injection Symjepi, which will compete with Mylan’s EpiPen to treat allergic reactions. The drugmaker plans to launch Symjepi in the second half of 2017. (WSJ)
2. Ovarian cancer patients who took Clovis Oncology’s PARP inhibitor Rubraca had a median survival of 10.8 months without the disease worsening, compared to 5.4 months for those who to took a placebo, according to a late-stage study of 564 patients by the drugmaker. Clovis plans to apply for Rubraca’s label expansion by this October. (Reuters)
3. Hedge fund manager John Paulson joined Valeant Pharmaceuticals’ board of directors. After the departure of key investor Bill Ackman in March, Paulson & Co. became the drugmaker’s largest shareholder, controlling about $10 billion in assets. (Bloomberg)
4. New biotech firm Idorsia has secured the backing of Johnson & Johnson, which has invested $1 billion in research and development through its $30 billion acquisition of Actelion. (Endpoints News)
5. The state of California will award local health clinics $20 million in emergency grants to counteract potential cuts by the Trump administration. (Reuters)
